Rituximab for the first-line maintenance treatment of follicular non-Hodgkin's lymphoma: A nice single technology appraisal

PharmacoEconomics

Volumn 31, Issue 5, 2013, Pages 403-413

  Greenhalgh, Janette ^a   Bagust, Adrian ^a   Boland, Angela ^a   Blundell, Michaela ^a   Oyee, James ^a   Beale, Sophie ^a   Dundar, Yenal ^a   Hockenhull, Juliet ^a   Proudlove, Chris ^b   Chu, Patrick ^c  

^a UNIVERSITY OF LIVERPOOL   (United Kingdom)

^b North West Medicines Information Centre ^*  (United Kingdom)

^c ROYAL LIVERPOOL UNIVERSITY HOSPITAL   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

RITUXIMAB; ANTINEOPLASTIC AGENT; MONOCLONAL ANTIBODY;

CANCER CHEMOTHERAPY; CANCER SURVIVAL; COST EFFECTIVENESS ANALYSIS; DRUG COST; DRUG EFFICACY; DRUG INDUSTRY; FOLLICULAR LYMPHOMA; HUMAN; MAINTENANCE THERAPY; MULTICENTER STUDY (TOPIC); OPEN STUDY; OVERALL SURVIVAL; PHASE 3 CLINICAL TRIAL (TOPIC); PRIORITY JOURNAL; PROGRESSION FREE SURVIVAL; REVIEW; SIMULATION; TREATMENT DURATION; COST BENEFIT ANALYSIS; DISEASE FREE SURVIVAL; ECONOMICS; LYMPHOMA, FOLLICULAR; PROBABILITY; STATISTICAL MODEL; SURVIVAL; TREATMENT OUTCOME; UNITED KINGDOM;

ANTIBODIES, MONOCLONAL, MURINE-DERIVED; ANTINEOPLASTIC AGENTS; COST-BENEFIT ANALYSIS; DISEASE-FREE SURVIVAL; GREAT BRITAIN; HUMANS; LYMPHOMA, FOLLICULAR; MARKOV CHAINS; MODELS, ECONOMIC; SURVIVAL; TREATMENT OUTCOME;

EID: 84877955717     PISSN: 11707690     EISSN: 11792027     Source Type: Journal    
DOI: 10.1007/s40273-013-0043-8     Document Type: Review

References (55)

1. National Institute for Health and Clinical Excellence. Guide to the single technology (STA) process. London: NICE; 2006. http://www.nice.org.uk/ page.aspx?o=STAprocessguide. Accessed 1 Sep 2010.
2. Sculpher M. Single technology appraisal at the UK National Institute for Health and Clinical Excellence: a source of evidence and analysis for decision making internationally. Pharmacoeconomics. 2010;28(5):347-9.
3. Rodgers M, Griffin S, Paulden M, et al. Alitretinoin for severe chronic hand eczema: a NICE single technology appraisal. Pharmacoeconomics. 2010;28(5):351-62.
4. Bagust A, Greenhalgh J, Boland A, et al. Cetuximab for recurrent and/or metastatic squamous cell carcinoma of the head and neck: a NICE single technology appraisal. Pharmacoeconomics. 2010;28(6):439-48.
5. Stevenson M, Pandor A. Febuxostat for the management of hyperuricemia in patients with gout: a NICE single technology appraisal. Pharmacoeconomics. 2011;29(2):133-40.
6. Scotland G, Waugh N, Royle P, et al. Denosumab for the prevention of osteoporotic fractures in post-menopausal women: a NICE single technology appraisal. Pharmacoeconomics. 2011;29(11):951-61.
7. Dickson R, Bagust A, Boland A, et al. Erlotinib monotherapy for the maintenance treatment of non-small cell lung cancer after previous platinum-containing chemotherapy: a NICE single technology appraisal. Pharmacoeconomics. 2011;29(12):1051-62.
8. McKenna C, Maund E, Sarowar M, et al. Dronedarone for the treatment of atrial fibrillation: a NICE single technology appraisal. Pharmacoeconomics. 2012;30(1):35-46.
9. Holmes M, Carroll C, Papaioannou D. Dabigatran etexilate for the prevention of venous thromboembolism in patients undergoing elective hip and knee surgery: a NICE single technology appraisal. Pharmacoeconomics. 2012;30(2):137-46.
10. Yang H, Craig D, Epstein D, et al. Golimumab for the treatment of psoriatic arthritis: a NICE single technology appraisal. Pharmacoeconomics. 2012;30(4):257-70.
11. Boyers D, Jia X, Jenkinson D, et al. Eltrombopag for the treatment of chronic immune or idiopathic thrombocytopenic purpura: a NICE single technology appraisal. Pharmacoeconomics. 2012;30(6):483-95.
12. Burch J, Griffin S, McKenna C, Walker S, Paton J, Wright K, et al. Omalizumab for severe persistent asthma in children aged 6-11 years: a NICE single technology appraisal. Pharmacoeconomics. 2012;30(11):991-1004.
13. Whyte S, Pandor A, Stevenson M. Bevacizumab for metastatic colorectal cancer: a NICE single technology appraisal. Pharmacoeconomics. 2012;30(12):1119-32.
14. Kilonzo M, Hislop J, Elders A, Fraser C, Bissett D, McClinton S, et al. Pazopanib for the first-line treatment of patients with advanced and/or metastatic renal cell carcinoma: a NICE single technology appraisal. Pharmacoeconomics. 2013;31(1):15-24.
15. Craig D, Rice S, Paton F, et al. Retigabine for the adjunctive treatment of adults with partial onset seizures in epilepsy with and without secondary generalisation: a NICE single technology appraisal. Pharmacoeconomics. 2013;31(2):101-10.
16. Spackman E, Rice S, Norman G, Suh D-C, Eastwood A, Palmer S. Trastuzumab for the treatment of HER2 positive metastatic gastric cancer: a NICE single technology appraisal. Pharmacoeconomics. 2013;31(3):185-94.
17. Rafia R, Simpson E, Stevenson M, Papaioannou D. Trabectedin for the treatment of advanced metastatic soft tissue sarcoma: a NICE single technology appraisal. Pharmacoeconomics. 2013. doi: 10.1007/s40273-013-0044-7.
18. Simpson EL, Fitzgerald P, Evans P, et al. Bivalirudin for the treatment of ST-segment elevation myocardial infarction: a NICE single technology appraisal. Pharmacoeconomics. 2013;31(4):269-75.
19. Armstrong N, Manuela J, van Asselt T, et al. Golimumab for the treatment of ankylosing spondylitis: a NICE single technology appraisal. Pharmacoeconomics. 2013. doi: 10.1007/s40273-013-0049-2.
20. Tosh J, Archer R, Davis S, et al. Golimumab for the treatment of rheumatoid arthritis after the failure of previous disease-modifying anti-rheumatic drugs: a NICE single technology appraisal. Pharmacoeconomics (in press).
21. Kearns B, Lloyd-Jones M, Stevenson M, Littlewood C. Cabazitaxel for the second-line treatment of metastatic hormone-refractory prostate cancer: a NICE single technology appraisal. Pharmacoeconomics. 2013. doi: 10.1007/s40273-013- 0050-9.
22. Faria R, Spackman E, Burch J, Corbacho B, Todd D, Pepper C, et al. Dabigatran for the prevention of stroke and systemic embolism in atrial fibrillation: a NICE single technology appraisal. Pharmacoeconomics (in press).
23. National Institute for Health and Clinical Excellence. Lymphoma (follicular non-Hodgkin's)-rituximab: final appraisal determination. London: NICE; 2011. http://guidance.nice.org.uk/TA/Wave19/59. Accessed 1 Sep 2011.
24. Cancer Research UK. Non-Hodgkin lymphoma (NHL) statistics (UK 2010). London: Cancer Research UK; 2010. http://info.cancerresearchuk.org/cancerstats/ types/nhl/index.htm?script=true. Accessed 1 Sep 2010.
25. National Cancer Institute, U.S. National Institutes of Health. Surveillance Epidemiology and End Results: SEER stat fact sheets - non-Hodgkin lymphoma. Bethesda: National Cancer Institute; 2012. http://seer.cancer.gov/ statfacts/html/nhl.html. Accessed 1 May 2012.
26. Australian Institute of Health and Welfare, Australasian Association of Cancer Registries. Cancer in Australia: an overview, 2008 [cancer series no.46]. Canberra: AIHW; 2008. http://www.aihw.gov.au/publication-detail/?id=6442468196. Accessed 1 May 2012.
27. Non-Hodgkin's Lymphoma Cyberfamily. NHL statistics. http://www. nhlcyberfamily.org/statistics.htm#england. 2012. Accessed 1 May 2012.
28. A predictive model for aggressive non-Hodgkin's lymphoma. The International non-Hodgkin's Lymphoma Prognosis Factors Project. N Engl J Med. 1993;329(14):987-94.
29. National Institute for Health and Clinical Excellence. Follicular non-Hodgkin's lymphoma - rituximab: final scope. London: NICE; 2010. http://guidance.nice.org.uk/TA/Wave19/59/Scope/pdf/English. Accessed 25 Aug 2010.
30. Shipp MA, Mauch PM, Harris NL, editors. Non-Hodgkin's lymphomas. 5th ed. Philadelphia: Lippincott-Raven; 1997.
31. Horning SJ, Rosenberg S. Natural history of initially untreated low-grade non-Hodgkin's lymphoma. N Engl J Med. 1984;311:1471-5.
32. Lister T. The management of follicular lymphoma. Ann Oncol. 1991;2(Suppl. 2):131-5.
33. Dillman RO, Chico S. Improved survival of lymphoma patients after introduction of rituximab. Blood. 2005;106: abstract 4650.
34. Fischer RI, LeBlanc M, Press OW, Maloney DG, Unger JM, Miller TP. New treatment options have changed the survival of patients with follicular lymphoma. J Clin Oncol. 2005;23(33):8447-52.
35. Liu Q, Fayad L, Hagemeister FB, Alma Rodriguez M, Younes A, Pro B, et al. Stage IV indolent lymphoma: 25 years of treatment progress. Blood. 2003;102(398a): abstract 1446.
36. Swenson WT, Wooldridge JE, Lynch CF, Forman-Hoffman VL, Chrischilles E, Link BK. Improved survival of follicular lymphoma patients in the United States. J Clin Oncol. 2005;23:5019-26.
37. Gallagher CJ, Gregory WM, Jones AE, Stansfeld AG, Richards MA, Dhaliwal HS, et al. Follicular lymphoma: prognostic factors for response and survival. J Clin Oncol. 1986;4:1470-80.
38. Wahl R, Kaminski M, Zelenetz A, Vose J, Press O, Goldsmith S, et al. Each subsequent therapy results in diminishing response rate and duration of response in low grade or transformed low grade non-Hodgkin's lymphoma. Proc Am Soc Clin Oncol. 2001; 20: abstract 1165.
39. van Oers M, Klasa R, Marcus RE, Wolf M, Kimby E, Gascoyne RD, et al. Rituximab maintenance improves clinical outcome of relapsed/resistant follicular non-Hodgkin lymphoma in patients both with and without rituximab during induction: results of a prospective randomized phase 3 intergroup trial. Blood. 2006;108(10):3295-301.
40. van Oers MHJ, van Glabbeke M, Giurgea L, Klasa R, Marcus RE, Wolf M, et al. Rituximab maintenance treatment of relapsed/resistant follicular non-Hodgkin's lymphoma: long-term outcome of the EORTC 20981 phase III randomized intergroup study. J Clin Oncol. 2010;28(17):2853-8.
41. European Medicines Agency. Mabthera (rituximab). London: EMA; 2012. http://www.ema.europa.eu/ema/index.jsp?curl=pages/medicines/human/medicines/ 000165/human-med-000897.jsp&mid=WC0b01ac058001d124. Accessed 1 May 2012.
42. Roche Ltd. Rituximab: clinical study report (M018264)-No.10347952010.
43. Salles G, Seymour JF, Offner F, Lopez-Guillermo A, Belada D, Xerri L, et al. Rituximab maintenance for 2 years in patients with high tumour burden follicular lymphoma responding to rituximab plus chemotherapy (PRIMA): a phase 3, randomised controlled trial. Lancet. 2011;377(9759):42-51.
44. Functional Assessment of Chronic Illness Therapy. FACIT. Elmhurst: FACIT; 2010. http://www.facit.org/FACITOrg/Questionnaires. Accessed 1 Sep 2010.
45. European Organisation for Research and Treatment of Cancer. EORTC QLQ-C30. Brussels: EORTC; 2010. http://groups.eortc.be/qol/eortc-qlq-c30. Accessed 1 Sep 2010.
46. Bassler D, Briel M, Montori VM, Lane M, Glasziou P, Zhou Q, et al. Stopping randomized trials early for benefit and estimation of treatment effects: systematic review and meta-regression analysis. JAMA. 2010;303(12):1180-7.
47. National Institute for Health and Clinical Excellence. Rituximab for the treatment of relapsed or refractory stage III or IV follicular non-Hodgkin's lymphoma (review of technology appraisal guidance 37):TA137. London: NICE; 2008. http://guidance.nice.org.uk/TA137/Guidance/pdf/English. Accessed 25 Aug 2010.
48. Wild D. Utility values in follicular lymphoma - Oxford Outcomes [unpublished report by Oxford Outcomes prepared for Roche UK]. Oxford: Oxford Outcomes; 2005.
49. Department of Health. NHS reference costs 2008-2009. London: Department of Health; 2010. http://www.dh.gov.uk/en/Publicationsandstatistics/Publications/ PublicationsPolicyAndGuidance/DH-111591. Accessed 25 Aug 2010.
50. Royal Pharmaceutical Society of Great Britain. British National Formulary: BNF 56-59. London: BMJ Publishing, RCPCH Publications, Royal Pharmaceutical Society of Great Britain; 2010. http://www.bnf.org/bnf/. Accessed 6 July 2010.
51. Nabhan C, Smith SM, Kahl BS. Maintenance rituximab in follicular non-Hodgkin lymphoma: facts and controversies. Leukemia Lymphoma. 2012;53(5):770-8.
52. National Institute for Health and Clinical Excellence. Follicular non-Hodgkin's lymphoma - rituximab: appraisal consultation document. London: NICE; 2010. http://guidance.nice.org.uk/TA/Wave19/59/Consultation/ DraftGuidance1. Accessed 1Oct 2011.
53. European Medicines Agency. Assessment report for MabThera (rituximab) [procedure no. EMEA/H/C/000165/II/0069]. London: EMA; 2010. http://www.ema. europa.eu/docs/en-GB/document-library/EPAR-Assessment-Report-Variation/human/ 000165/WC500099489.pdf. Accessed 1 Oct 2011.
54. Greenhalgh J, Bagust A, Boland A, Blundell M, Oyee J, Dundar Y, et al. Rituximab for the first-line maintenance treatment of follicular non-Hodgkin's lymphoma. Southampton: NETSCC; 2012.
55. Liverpool Reviews and Implementation Group. Rituximab for the first-line maintenance treatment of patients with follicular non-Hodgkin's lymphoma: addendum [ERG critique of extra information submitted by Roche]. London: NICE; 2011. http://www.nice.org.uk/nicemedia/live/11863/54540/54540.pdf. Accessed 1 Oct 2011.